Fasikl

Fasikl operates at the intersection of neurotechnology, medical devices, therapeutics, and artificial intelligence. Its clearest commercial position is in noninvasive treatment for essential tremor, where the FDA-cleared Felix NeuroAI Wristband combines a familiar wearable form factor with AI-controlled peripheral nerve stimulation. That approach differentiates Fasikl from implant-focused neuromodulation companies such as Neuros Medical by avoiding an implanted therapy, while placing it in the same broader competitive landscape as wearable tremor-therapy providers such as Cala Health. Fasikl’s differentiation is not only the device but also the stated combination of neural engineering, machine learning, patient-centered design, and real-world evidence. The company also maintains a more exploratory nerve-computer interface program, MindForce, intended to decode peripheral nerve signals for control of robotic limbs, computers, and assistive devices. Competitive strength therefore appears concentrated in regulatory progress and technology breadth rather than demonstrated volume.

Fasikl’s trajectory shows a progression from university-linked neural engineering research toward regulated therapeutic commercialization. Founded in 2019, the company raised $5 million in November 2021, followed by $10 million in March 2023 and $18.3 million in September 2024. The $26.56 million Series B announced on Sep 17, 2025 was the largest disclosed round and lifted cumulative funding to $59.86 million. The principal inflection point was 2025: FDA clearance for Felix was announced on Jul 1, 2025, initial availability by prescription in select U.S. regions was reported on Oct 20, 2025, and clinical evidence related to daily function was highlighted in JAMA Neurology coverage the same day. This sequence suggests a shift from product development and regulatory preparation to early commercialization. Fasikl is also preserving longer-term platform optionality through MindForce, an investigational nerve-computer interface, and patent applications related to peripheral nerve signal acquisition and adaptive electrical stimulation. Hiring for billing, provider support, and client support roles is consistent with building the infrastructure required for prescription fulfillment and patient-facing operations. However, public information does not quantify revenue, adoption, headcount growth, or reimbursement coverage.